tiprankstipranks
Fujian Haixi Pharmaceuticals Co., Ltd. Class H (HK:2637)
:2637
Hong Kong Market
2637
Fujian Haixi Pharmaceuticals Co., Ltd. Class H
RESEARCH TOOLSreports

Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

2637 Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Fujian
Haixi Pharmaceuticals Co., Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2637 Stock 12 Month Forecast

Average Price Target

$304.53
Based on 6 Wall Street analysts offering 12 month price targets for Fujian Haixi Pharmaceuticals Co., Ltd. Class H in the last 3 months. The average price target is 304.53 with a high forecast of 346.75 and a low forecast of 264.30. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"103":"103","164":"164","225":"225","286":"286","347":"347"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":346.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">346.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":304.52666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">304.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":264.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">264.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[103,164,225,286,347],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,211,221.44230769230768,231.8846153846154,242.32692307692307,252.76923076923077,263.21153846153845,273.65384615384613,284.0961538461538,294.53846153846155,304.9807692307692,315.4230769230769,325.86538461538464,336.30769230769226,{"y":346.75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,211,218.19435897435898,225.38871794871795,232.58307692307693,239.77743589743588,246.97179487179486,254.16615384615383,261.3605128205128,268.55487179487176,275.74923076923073,282.9435897435897,290.1379487179487,297.33230769230767,{"y":304.52666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,211,215.1,219.2,223.3,227.4,231.5,235.6,239.7,243.8,247.9,252,256.1,260.2,{"y":264.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":104.2,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":104.2,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":104.2,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":104.2,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":104.2,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":119.8,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":128,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":136,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":134.4,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":142.2,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":180.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":261,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":211,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target346.75Average Price Target304.53Lowest Price Target264.30
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Huafu Securities Analyst forecast on HK:2637
Unknown Analyst
Huafu Securities
Not Ranked
Huafu Securities
HK$264.3
Buy
―
Reiterated
06/13/26
Huafu Securities Sticks to Their Buy Rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)
CMB International Securities Analyst forecast on HK:2637
Jill Wu
CMB International Securities
CMB International Securities
HK$280
Buy
―
Initiated
06/10/26
Haixi Pharma Initiated at Buy on Innovative Retinal and Oncology Pipeline; DCF‑Backed Target Price Set at HK$280
Northeast Securities Analyst forecast on HK:2637
Unknown Analyst
Northeast Securities
Not Ranked
Northeast Securities
HK$346.75
Buy
―
Reiterated
05/08/26
Northeast Securities Reaffirms Their Buy Rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)
Guohai Securities Analyst forecast on HK:2637
Unknown Analyst
Guohai Securities
Not Ranked
Guohai Securities
HK$339.55
Buy
―
Reiterated
05/06/26
Guohai Securities Sticks to Its Buy Rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)
Shenwan Hongyuan Analyst forecast on HK:2637
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$298.28
Buy
―
Reiterated
04/24/26
Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) Receives a Buy from Shenwan Hongyuan
SWS Res Analyst forecast on HK:2637
Unknown Analyst
SWS Res
Not Ranked
SWS Res
HK$298.28
Buy
―
Reiterated
04/23/26
Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) Receives a Buy from SWS Res
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Huafu Securities Analyst forecast on HK:2637
Unknown Analyst
Huafu Securities
Not Ranked
Huafu Securities
HK$264.3
Buy
―
Reiterated
06/13/26
Huafu Securities Sticks to Their Buy Rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)
CMB International Securities Analyst forecast on HK:2637
Jill Wu
CMB International Securities
CMB International Securities
HK$280
Buy
―
Initiated
06/10/26
Haixi Pharma Initiated at Buy on Innovative Retinal and Oncology Pipeline; DCF‑Backed Target Price Set at HK$280
Northeast Securities Analyst forecast on HK:2637
Unknown Analyst
Northeast Securities
Not Ranked
Northeast Securities
HK$346.75
Buy
―
Reiterated
05/08/26
Northeast Securities Reaffirms Their Buy Rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)
Guohai Securities Analyst forecast on HK:2637
Unknown Analyst
Guohai Securities
Not Ranked
Guohai Securities
HK$339.55
Buy
―
Reiterated
05/06/26
Guohai Securities Sticks to Its Buy Rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)
Shenwan Hongyuan Analyst forecast on HK:2637
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$298.28
Buy
―
Reiterated
04/24/26
Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) Receives a Buy from Shenwan Hongyuan
SWS Res Analyst forecast on HK:2637
Unknown Analyst
SWS Res
Not Ranked
SWS Res
HK$298.28
Buy
―
Reiterated
04/23/26
Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) Receives a Buy from SWS Res
Stocks with the Highest Top Analyst Consensus in the Sector
Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fujian Haixi Pharmaceuticals Co., Ltd. Class H

3 Months
Jill WuCMB International Securities
Success Rate
0/1 ratings generated profit
0%
Average Return
-0.80%
Copying Jill Wu's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -0.80% per trade.
1 Year
Jill WuCMB International Securities
Success Rate
0/1 ratings generated profit
0%
Average Return
-0.80%
Copying Jill Wu's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -0.80% per trade.
2 Years
Jill WuCMB International Securities
Success Rate
0/1 ratings generated profit
0%
Average Return
-0.80%
Copying Jill Wu's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -0.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2637 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
1
Buy
0
0
2
4
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
2
4
6
In the current month, 2637 has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2637 average Analyst price target in the past 3 months is 304.53.
Each month's total comprises the sum of three months' worth of ratings.

2637 Financial Forecast

No data currently available

2637 Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

2637 Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

2637 Stock Forecast FAQ

What is HK:2637’s average 12-month price target, according to analysts?
Based on analyst ratings, Fujian Haixi Pharmaceuticals Co., Ltd. Class H’s 12-month average price target is 304.53.
    What is HK:2637’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for HK:2637, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Fujian Haixi Pharmaceuticals Co., Ltd. Class H a Buy, Sell or Hold?
        Fujian Haixi Pharmaceuticals Co., Ltd. Class H has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Fujian Haixi Pharmaceuticals Co., Ltd. Class H’s share price target?
          The average share price target for Fujian Haixi Pharmaceuticals Co., Ltd. Class H is 304.53. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is 346.75 ,and the lowest forecast is 264.30. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Fujian Haixi Pharmaceuticals Co., Ltd. Class H?
            Fujian Haixi Pharmaceuticals Co., Ltd. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
              How can I buy shares of Fujian Haixi Pharmaceuticals Co., Ltd. Class H?
              To buy shares of HK:2637, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.